Navigation Links
FDA Approves New Dosage Strength for INTELENCE®
Date:1/3/2011

ital, phenytoin, rifampin, rifapentine, rifabutin (when part of a regimen containing protease inhibitor/ritonavir) or products containing St. John's wort (Hypericum perforatum)
  • Coadministration of INTELENCE with other agents such as substrates, inhibitors, or inducers of CYP3A, CYP2C9, CYP2C19, and/or P-glycoprotein may alter the therapeutic effect or adverse reaction profile of INTELENCE or the coadministered drug(s)

  • This is not a complete list of potential drug interactionsYou are encouraged to report negative side effects of prescription drugs to the FDA.  Visit www.fda.gov/medwatch, or call 1-800-FDA-1088Please see full Prescribing Information for more details. Full prescribing information is also available at www.INTELENCE-info.com. About Tibotec Therapeutics Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, L.P., headquartered in Titusville, N.J., is dedicated to delivering innovative virology therapeutics that help healthcare professionals address serious unmet needs in people living with HIV.

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Centocor Ortho Biotech Products, L.P.'s and/or Johnson & Johnson's expectations and projections.  Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health
    '/>"/>

    SOURCE Tibotec Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
    2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
    3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
    4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
    5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
    6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
    7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
    8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
    9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
    10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
    11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... -- Research and Markets ( ... "12th Annual Report and Survey of Biopharmaceutical ... offering. The 2015 12th Annual Report ... is the most recent study of biotherapeutic developers ... capacity and production. The report contains the industry,s ...
    (Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on ... their offering. Developed by Novo Nordisk, ... is an important drug for the treatment of ... a fast- acting insulin analog, starts working fast ...
    (Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... MYL ) shareholder vote regarding its planned unsolicited ... Mylan,s offer to Perrigo shareholders have always been, and ... reflection of the value available to Perrigo shareholders, and ... has allowed its shareholders to consider," said Joseph ...
    Breaking Medicine Technology:12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
    ... Company, Limited (hereafter, Daiichi Sankyo), announced today that the ... (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 ... Welfare in Japan. Edoxaban, which is being ... anticoagulant that specifically, reversibly and directly inhibits the enzyme, ...
    ... Ontario, April 21, 2011 Valeant Pharmaceuticals International, Inc. ... the following statement to shareholders of Cephalon, Inc. (NASDAQ: ... today, the Cephalon Board of Directors stated that it ... Company,s alternatives and options – and is focused on ...
    Cached Medicine Technology:Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 2Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 3Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 4Valeant Pharmaceuticals Responds to Cephalon Board's Letter 2Valeant Pharmaceuticals Responds to Cephalon Board's Letter 3Valeant Pharmaceuticals Responds to Cephalon Board's Letter 4
    (Date:8/30/2015)... , ... August 30, 2015 , ... Scientists in France ... also a range of digestive cancers. Surviving Mesothelioma has just posted an article on ... the University of Caen measured the cancer incidence among 2,024 French asbestos plant workers ...
    (Date:8/30/2015)... ... August 30, 2015 , ... Certified Nutrition Businessman Reid Eckert ... International and InHealth media is a global sales and communications firm that offers U.S. ... to continue our business relationship with Mr. Reid Eckert, as his interpretation of the ...
    (Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
    (Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed ... p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about ... signature. , Clinical trial sites can now use audio, video and ...
    (Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... briefs due to insufficient scrotal support and protection against dribbled urine and sweat. ... inventor from Manhasset Hills, N.Y. , The EASY ACCESS DRYNESS ENHANCED MEN'S UNDERGARMENT ...
    Breaking Medicine News(10 mins):Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Modified Men’s Underwear Promote More Comfort and Hygiene - Designed by InventHelp Client (LGI-1968) 2
    ... segment of the driving population, and their eye care ... assessing their ability to drive safely. ... led a multidisciplinary University of Michigan (U-M) study team, ... unit of the U-M Transportation Research Institute, who surveyed ...
    ... , MONDAY, Aug. 22 (HealthDay News) -- A drive to ... productive job search methods are the three key ingredients to ... a "down" economy. That,s the take-home message of a ... of the American Sociological Association in Las Vegas. "Although ...
    ... with hepatocellular carcinoma (HCC) is achievable using 90Y-resin ... across Europe showed that the procedure is likely ... including patients with advanced liver cancer and with ... to dateare published in the September issue of ...
    ... a part of everyday life for children in the United ... hazard for their child, they may not be aware just ... A new study conducted by researchers at the Center ... Nationwide Children,s Hospital found that approximately 5,200 children and adolescents ...
    ... , MONDAY, Aug. 22 (HealthDay News) -- A new ... likely to avoid crime. To reach this finding, researchers at ... nearly 15,000 students in grades 7 to 9. About 29 percent ... and 18 percent said they had used at least one illegal ...
    ... hormone therapy (HT) use among women aged 50 to 64 ... Published early online in CANCER , a peer-reviewed journal ... women stop seeing their doctor for HT prescriptions, physicians do ... are due. Since rates were first measured in 1987, ...
    Cached Medicine News:Health News:Kellogg researcher helping eye care providers better assess driving in older adults 2Health News:Study Shows Key Ways Young Adults Can Find, Keep a Job 2Health News:Radioembolization improves chance of survival for liver cancer patients 2Health News:New study examines window fall-related injuries among youth 2Health News:Happy Teens Usually Crime-Free Teens, Study Finds 2Health News:Drop in hormone therapy use linked with drop in mammogram rates 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: